Zhejiang Hangkang Pharmaceutical Co Ltd.

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation fenelazol tablets (20 mg, manufactured by Zhejiang Hangkang Pharmaceutical Co., Ltd.) and the reference formulation fenelazol tablets (Kerendia®, 20 mg, manufactured by Bayer AG, licensed by Bayer AG) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary Objective: To investigate the safety of a single oral dose of the test formulation fenelazol tablets and the reference formulation fenelazol tablets (Kerendia®) in healthy adult participants under fasting conditions.

The main purpose of the study is to use the linezolid tablets (600 mg) certified by Pfizer Pharmaceuticals.LCC as the reference preparation and the linezolid tablets (600 mg) developed by Zhejiang Hangkang Pharmaceutical Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and fed state through a single-center, single-dose, randomized, open, two-period, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The main purpose of the study is to use AstraZeneca AB's licensed saxagliptin tablets (specification: 5 mg, trade name: ONGLYZA) as the reference preparation and Zhejiang Hangkang Pharmaceutical Co., Ltd.'s saxagliptin tablets (specification: 5 mg) as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and fed state through a single-center, single-dose, randomized, open, two-period, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.